John McGee
Scientific Co-Founder, Executive Vice President & Head of PlatformMr. John McGee, Ph.D., is Scientific Co-Founder, Executive Vice President & Head of Platform of Parabilis Medicines, Inc. from 2025. Mr. McGee served as Scientific Co-Founder & Vice President of De Novo Discovery of Fog Pharmaceuticals, Inc. since 2022 until 2025. He has more than a decade of experience in developing and applying new discovery and optimization technologies for helically constrained (Helicon) peptide therapeutics. Prior to joining FogPharma, he was a postdoctoral research fellow at Harvard University, where he worked in the laboratory of Dr. Greg Verdine. At Harvard, he performed foundational work on both the de novo screening and multiplexing platforms that now form the core of FogPharma’s rapid early discovery engine. These studies also led to the development of the tandem paired-helix Griptide platform, now licensed by FogPharma; John made the key discovery of Griptides that bind a range of active RAS isoforms and oncogenic mutants with picomolar affinity. He holds a B.S. in chemistry from Stanford University, where he worked in the laboratory of Dr. Eric Kool and a Ph.D. in biochemistry from Harvard University, where he studied with Dr. Greg Verdine.
Positions
- Company NameParabilis Medicines, Inc.Stock CodePBLSPositionScientific Co-Founder, Executive Vice President & Head of PlatformColleagues
- MMMathai MammenCEO, President, Treasurer & Chairman
- TLTeresa L. JurgensenExecutive VP, Secretary & General Counsel
- TRThomas Rodolpho KotarakosChief Financial Officer
- RMRohin MhatreChief Technical Operations Officer
- KYKrishna YeshwantIndependent Non-Employee Director
- EMEdward M. FitzgeraldIndependent Non-Employee Director
- AAAlexis A. BorisyIndependent Non-Employee Director
- BLBarbara L. WeberIndependent Non-Employee Director
